




# BMJ Open Implementation of medicines pricing policies in sub-Saharan Africa: protocol for a systematic review

Tolib Mirzoev <sup>1</sup>, Augustina Koduah,<sup>2</sup> Anna Cronin de Chavez,<sup>1</sup> Leonard Baatiema,<sup>3</sup> Anthony Danso-Appiah,<sup>3</sup> Tim Ensor <sup>1</sup>, Irene Akua Agyepong,<sup>4</sup> Judy M Wright <sup>5</sup>, Irene A Kretchy,<sup>2</sup> Natalie King<sup>5</sup>

**To cite:** Mirzoev T, Koduah A, Cronin de Chavez A, *et al.* Implementation of medicines pricing policies in sub-Saharan Africa: protocol for a systematic review. *BMJ Open* 2021;**11**:e044293. doi:10.1136/bmjopen-2020-044293

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2020-044293>).

TM and AK are joint first authors.

Received 29 August 2020

Revised 16 January 2021

Accepted 11 February 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

<sup>1</sup>Nuffield Centre for International Health and Development, University of Leeds, Leeds, UK

<sup>2</sup>School of Pharmacy, University of Ghana, Legon, Greater Accra, Ghana

<sup>3</sup>School of Public Health, University of Ghana, Accra-Legon, Ghana

<sup>4</sup>Research and Development Division, Ghana Health Service, Accra, Greater Accra, Ghana

<sup>5</sup>Leeds Institute of Health Sciences, University of Leeds, Leeds, UK

## Correspondence to

Professor Tolib Mirzoev; [t.mirzoev@leeds.ac.uk](mailto:t.mirzoev@leeds.ac.uk)

## ABSTRACT

**Introduction** Ensuring universal availability and accessibility of medicines and supplies is critical for national health systems to equitably address population health needs. In sub-Saharan Africa (SSA), this is a recognised priority with multiple medicines pricing policies enacted. However, medicine prices have remained high, continue to rise and constrain their accessibility. In this systematic review, we aim to identify and analyse experiences of implementation of medicines pricing policies in SSA. Our ambition is for this evidence to contribute to improved implementation of medicines pricing policies in SSA.

**Methods and analysis** We will search: Medline, Web of Science, Scopus, Global Health, Embase, Cairn, Info International Edition, Erudit and African Index Medicus, the grey literature and reference from related publications. The searches will be limited to literature published from the year 2000 onwards that is, since the start of the Millennium Development Goals. Published peer-reviewed studies of implementation of medicines pricing policies in SSA will be eligible for inclusion. Broader policy analyses and documented experiences of implementation of other health policies will be excluded. The team will collaboratively screen titles and abstracts, then two reviewers will independently screen full texts, extract data and assess quality of the included studies. Disagreements will be resolved by discussion or a third reviewer. Data will be extracted on approaches used for policy implementation, actors involved, evidence used in decision making and key contextual influences on policy implementation. A narrative approach will be used to synthesise the data. Reporting will be informed by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols guideline.

**Ethics and dissemination** No ethics approvals are required for systematic reviews.

Results will be disseminated through academic publications, policy briefs and presentations to national policymakers in Ghana and made widely across countries in SSA.

**PROSPERO registration number** CRD42020178166.

## INTRODUCTION

The current agenda of Universal Health Coverage highlights the importance of access

## Strengths and limitations of this study

- This systematic review protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols guidelines.
- The review addresses a gap in the current knowledge of the determinants and outcomes of successful implementation of medicines pricing policies in sub-Saharan Africa (SSA).
- The focus on SSA will help with transferability of lessons across the different countries within the region, though this may lead to omission of important experiences for example from Asia and Latin America and may limit transferability of lessons outside the SSA.
- The search will be restricted to peer-reviewed published articles and grey literature, thus, relevant theses and conference abstracts are likely to be omitted and may affect the depth of evidence on the topic.
- The narrative synthesis approach reflects the nature of published evidence on the topic of policy implementation with no meta-analysis possible, and is a potential limitation of this review.

to safe, quality and affordable medicines as its key driver.<sup>1–3</sup> Increasing access to essential medicines through medicines pricing interventions is an issue of current health policy discourses.<sup>4–5</sup> In response, various policy initiatives have evolved to regulate medicine pricing and improve access.

Globally, different medicine pricing models and strategies exist. These include: generic or biosimilar price linking to originator products, non-proprietary prescribing and generic substitutions, tendering and pooled procurements, internal reference pricing, external price referencing or international price comparisons and managed-entry agreements.<sup>6–8</sup> Implementation of these medicine pricing policies may be dependent on in-country manufacturing capacity, pricing levels of the medicines, whether medicines

are generic or branded, and whether medicines are for outpatient or inpatient services.<sup>9</sup>

Many of these medicine pricing policies are being implemented in high-income countries. However, unlike in high-income countries, low-income and middle-income countries have less regulated and developed pharmaceutical markets and have different challenges in distribution and production.<sup>1</sup> In light of this, multiple medicine pricing models and strategies are required to achieve equitable access to safe, quality and affordable medicines,<sup>10</sup> particularly in sub-Saharan African (SSA) countries.<sup>10</sup>

## Rationale

Ensuring availability and accessibility of medicines is an important mechanism by which national health systems can equitably address health needs of their populations, including the poorest and the most vulnerable. In SSA, this is a recognised policy priority. For example, in the last two decades different medicines pricing policies were implemented in South Africa<sup>11 12</sup> and between 2012 and 2017, the Government of Ghana introduced four policies to improve access to medicines through medicine price regulation, and ultimately, health outcomes and quality of life. These policies are currently at different stages of their implementation and despite these efforts, medicine prices have remained high and continue to rise, making them inaccessible to a large proportion of populations. This raises questions as to why and how these policies are failing to achieve the desired outcomes.

In this systematic review, we will explore the effectiveness of implementation of medicines pricing policies in the SSA context. We want to identify which policies have been implemented and then explore three broad dimensions of their implementation. First, we want to understand what happened, that is, identify evidence on effective implementations of medicines pricing policies reflected in a reduction in prices and improvement in access to medicines and subsequently healthcare. Second, we want to understand how it happened, that is, we want to identify and unpack the implementation processes and approaches deployed in terms of their timing, participation of actors and role of evidence. Third, we want to understand why it happened. We want to identify and synthesise key reported facilitators and barriers to the implementation and understand how they affected the implementation of these policies within their respective contexts.

## Aim and objectives

In this systematic review, we will address the following overall question: what are the key determinants of implementation of medicines pricing policies in SSA countries? More specifically, we will answer four questions:

1. Which medicines pricing policies have been implemented in SSA and what are their key elements?

2. How have these policies been implemented (in relation to implementation approaches, processes, involvement of actors, role of evidence, etc)?
3. Which key facilitators and barriers affected the implementation of medicines pricing policies, and how?
4. Which implementation of medicines pricing policies in SSA are effective (in relation to reducing prices of medicines and improving access to services)?

This review is being undertaken during April 2020–May 2021 as part of the project on ‘Improving equitable access to essential medicines in Ghana through bridging the gaps in implementing medicines pricing policy’ (AMIPS project)—an National Institute for Health Research (NIHR) funded award received jointly by the University of Leeds, University of Ghana and the Ghana Health Service. The results of this review will be combined with results of policy analyses in Ghana and will inform engagements with key stakeholders on improving the implementation of the current policies and identification of future research and development priorities. Our ambition is for evidence from this review to contribute to improved implementation of medicines pricing policies across countries of SSA.

This protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Protocols (PRISMA-P) guidelines<sup>13</sup> and a PRISMA-P checklist is available as an online supplemental file.

## METHODS AND ANALYSIS

### Eligibility criteria

#### Studies

We will include empirical studies including Randomised Controlled Trials, quasi-experimental studies and cohort and cross-sectional studies. Reviews (scoping reviews, meta-syntheses, realist syntheses) will also be included and individual primary studies from the systematic reviews will be manually included as empirical literature. We will exclude opinion pieces and conceptual/theoretical publications which do not report documented empirical data from either primary studies or reviews.

Specific inclusion criteria will be: (1) focus on the medicines pricing policies that is, policies, strategies, interventions or plans which aim to improve affordability of medicines in the country. The link to improvements in access to healthcare may be implicit and is not a requirement; (2) focus on policy implementation, that is, either as part of the whole policy process (agenda-setting, development, implementation) or as an exclusive focus; (3) SSA country contexts, that is, either as part of the comparative studies or as a sole focus; (4) studies which were published since the agenda of Millennium Development Goals (MDGs) was initiated shortly before 2000 and (5) papers with relevant information available for analysis.

Specific exclusion criteria are: (1) policy analyses which focus solely on policy agenda-setting and development stages of the policy process; (2) studies from high-income country contexts and outside SSA; (3) studies conducted

2 years or more prior to 2000 but published after 2000 will be excluded in consideration of MDGs and Sustainable Development Goals (SDGs) agenda which started in 2000; (4) papers in languages where we are unable to have the resources for translation (the team has access to French, Spanish and Russian-speaking researchers) and (5) papers with no full text available for analysis.

### Participants

The participants to be covered in this review will be: policy-makers, implementers, service providers, patients and beneficiaries of successful implementation of medicines pricing policies (of any gender, age, ethnicity, socio-economic group, health status or urban–rural residence).

### Interventions

Implementation of medicines pricing policies, that is, policies, strategies, interventions or plans which aim to improve affordability of medicines in the country.

### Comparison

No comparison or control is applicable to this study.

### Outcomes

Successful implementation will be measured as reduction in medicines prices, and improved access to medicines along the supply chain. Any studies describing unsuccessful implementation will also be used to inform the lessons learnt.

### Study records

#### Searches

We will search the following databases: Medline (1946–present), Web of Science (1990–present), Scopus (1823–present), Global Health (1973–present), Embase (1947–present), Cairn.Info International Edition (all available years), Erudit (all available years) and African Index Medicus (all available years). The Medline search strategy is available as an online supplemental file. The search strategies will incorporate index terms from Medical Subject Headings (MeSH) and text words for the search concepts:

1. Sub-Saharan African Countries. This will include terms/synonyms for sub-Saharan Africa AND list of individual countries in the region.
2. Drug/Medicines pricing. This will include terms/synonyms for: medicines / pharmaceuticals / drugs / prescriptions AND pricing / cost / affordability / fees / purchase / rebate(s) / tariffs / incentives / benchmarking / reference pricing / payment / spend\* / expenditure / subsid\* / procurement.
3. Policy. This will include terms/synonyms for: policy / strategy / plan / framework / regulations / guidelines / rules / intervention / tax / exemption.
4. Implementation. This will include terms / synonyms for: Implementing / Implement(s) / Implementation approach(es) / Process(es) / Facilitator(s) / Barrier(s) / Factors / Determinants / context.

The searches will be limited to the literature published from the year 2000 and onwards. This is in consideration of the Millennium Development Goals agenda which started in 2000 with a clear focus on improving access to medicines and services. We will follow up on the references to the individual studies as required. We will manually search for the included references in relevant retrieved reviews (systematic reviews, scoping reviews, meta-syntheses, realist syntheses) for additional relevant studies for inclusion. In addition, we will search grey literature including global development websites: World Health Organisation's (WHO) Institutional Repository for Information Sharing (IRIS), World Bank, Knowledge, Evidence and Learning for Development (K4D) repository, Gates Foundation and contacts with experts in the field.

### Data management

We will upload all references identified through searches (electronic database and additional searches) into Endnote version X9. Once duplicates are removed, the remaining references will be exported into Rayyan (<https://rayyan.qcri.org/welcome>), an online free systematic review tool for screening.

### Screening

Titles and abstracts will be divided up across the review team and screened individually for eligibility using prespecified eligibility criteria flow chart, which is available in an online supplemental file. At least 20% of individually reviewed titles and abstracts will then be cross-checked by at least two members of the team. Full texts will be obtained for all the potentially relevant studies and screened by two members of the team independently, and disagreements will be resolved through discussion. Where necessary, a third member of the team will engage to help resolve disagreements.

### Data extraction

The following data will be extracted by two members of the review team into an appropriate data extraction form:

- ▶ Article information (full citation, year study was conducted, study type, setting / country).
- ▶ Medicine pricing policies studied (including which key elements the policies included).
- ▶ Documented effects on prices of medicines (including how identified and reported).
- ▶ Effects on access to medicines (including how identified and reported).
- ▶ Effects on access to healthcare (including how identified and reported).
- ▶ Implementation approach (including processes, actors involved and their roles and evidence used to inform implementation).
- ▶ Key influences on policy implementation (including facilitators and constraints and how they affected implementation).



### Quality assessment and risk of bias

Quality of each included study will be appraised. We will use validated quality assessment tools and the critical appraisal tools for relevant studies (qualitative and quantitative research) from the Joanna Briggs Institute [https://joannabriggs.org/ebp/critical\\_appraisal\\_tools](https://joannabriggs.org/ebp/critical_appraisal_tools). While at this point, we do not intend to change the actual criteria, the interpretation and application of the tools will be within the context of our study which focuses on key determinants of effective implementation of medicines pricing policies in SSA context. For example, clarity of focus will be assessed in relation to how the different aspects of policy implementation (processes, use of evidence, involvement of actors) are identified and consistently used in the reviewed papers.

A careful assessment of risk of bias in the included studies will be performed by two reviewers, who will first independently assess the quality of each study against each criterion. Results will be shared and agreed, and any disagreements will be addressed through engaging a third reviewer.

### Data synthesis and interpretation

#### Strategy for data synthesis

The main outcome in our study is the medicine pricing policy implementation. Policy implementation is typically done within a single country, but where the same policy is implemented in different countries, the analysis will take the specific context of the country into consideration.

In exploring the policy implementation, we will employ established policy theories and frameworks such as Walt and Gilson's policy triangle,<sup>14</sup> Baumgartner and Jones's punctuated equilibrium<sup>15</sup> and Lipsky's street-level bureaucracy,<sup>16</sup> and will also draw on further theories and frameworks developed or adapted within the reviewed papers.

Where possible, we will compare the effects of the policies in a quantitative synthesis. We anticipate, however, that the heterogeneity of reporting of outcomes and of context may make it impossible to conduct a meta-analysis. In such a situation we will focus on narrative synthesis.

While using qualitative or narrative synthesis approach,<sup>17</sup> data related to the medicines pricing policies will be extracted from the Introduction, Methods and possibly Results sections. Data on the effects of policy implementation and the policy implementation approaches, and key influences will be extracted from the Results and Discussion sections. Extracted data will be analysed thematically and will be structured around the specific questions of the review.

The interpretation of the results will follow the identified themes for each review question. For example, in answering the third review question we will divide the factors into facilitators and constraints and potentially will further subdivide them by their nature (eg, community issues, health systems issues, wider socioeconomic influences).

At the moment, we are not planning analysis of subgroups or subsets. However, depending on the breadth of extracted data we may consider subgroups such as geographical region (West Africa, East Africa, Southern Africa), setting (urban, rural) or categories of implementers (health facilities, pharmacies).

The cumulative strength of body of evidence will be assessed across the risk of bias and consistency, drawing on relevant approaches such as Grading of Recommendations Assessment, Development and Evaluation (GRADE).

### Patient and public involvement

No patient involved.

### ETHICS AND DISSEMINATION

Ethics approvals are not required for systematic reviews. However, ethics approvals for the wider AMIPS study within which this review is being undertaken have been granted by the ethics committees from the Ghana Health Service (ref GHS-ERC006/02/20) and the University of Leeds School of Medicine (ref MREC 19-060).

We will disseminate results through academic papers and stakeholder workshops in Ghana and other SSA countries where possible. In Ghana, the review results will be complemented by reviews of policy documents. The findings of this review will also be presented at scientific conferences such as the biannual Global Symposia on Health Systems Research and Thematic Working Groups of the Health Systems Global.

The results of this review will inform empirical investigations of implementation of medicines pricing policies in Ghana through the in-depth interviews and focus groups, and engagements and consultations with policy-makers on seeking ways of further improving the implementation of medicines pricing policies in Ghana.

**Twitter** Tolib Mirzoev @tmirzoev and Judy M Wright @jmwleeds

**Contributors** AK and TM jointly conceived the study; TM, AK, ACdC, LB, AD-A, TE, IAA, JMW, IAK and NK contributed to the review design and jointly wrote the protocol; TM, AK, ACdC, LB, AD-A, TE, IA, JMW, IAK and NK read and approved the final version of the manuscript. AK and TM will be the guarantors of the review.

**Funding** This research was commissioned by the National Institute for Health Research (NIHR) NIHR Global Health Policy and Systems Research Development Award using UK aid from the UK Government (grant number 130219). The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

# ORCID iDs

Tolib Mirzoev <http://orcid.org/0000-0003-2959-9187>

Tim Ensor <http://orcid.org/0000-0003-0279-9576>

Judy M Wright <http://orcid.org/0000-0002-5239-0173>

# REFERENCES

- Bigdeli M, Laing R, Tomson G. *Medicines and universal health coverage: challenges and opportunities: Biomed central*, 2015: 1–3.
- Ghebreyesus TA. All roads lead to universal health coverage. *Lancet Glob Health* 2017;5:e839–40.
- Wirtz VJ, Hogerzeil HV, Gray AL, et al. Essential medicines for universal health coverage. *The Lancet* 2017;389:403–76.
- World Health O, Regional Office for E. *Access to new medicines in Europe : technical review of policy initiatives and opportunities for collaboration and research*, 2015.
- World Health Organization. *Assessment of medicine pricing and reimbursement systems in health insurance schemes*, 2016.
- Bashaar M, Hassali F, Alrasheedy A. Efficacy of international approaches to medicine price regulation and control: a scoping review. *J Appl Pharm Sci* 2017;7:227–41.
- Leopold C, Vogler S, Mantel-Teeuwisse AK, et al. Differences in external price referencing in Europe: a descriptive overview. *Health Policy* 2012;104:50–60.
- Vogler S, Paris V, Ferrario A, et al. How can pricing and reimbursement policies improve affordable access to medicines? lessons learned from European countries. *Appl Health Econ Health Policy* 2017;15:307–21.
- Vogler S, Zimmermann N, de Joncheere K. Policy interventions related to medicines: survey of measures taken in European countries during 2010–2015. *Health Policy* 2016;120:1363–77.
- Nguyen TA, Knight R, Roughead EE, et al. Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries. *Health Policy Plan* 2015;30:267–80.
- Moodley R, Suleman F. Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis. *BMC Health Serv Res* 2019;19:576.
- Steyn R, Burger JR, Serfontein JHP, et al. Influence of a new reference-based pricing system in South Africa on the prevalence and cost of antidiabetic medicine: a pilot study. *Int J Pharm Pract* 2007;15:307–11.
- Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;349:g7647.
- Walt G, Gilson L. Reforming the health sector in developing countries: the central role of policy analysis. *Health Policy Plan* 1994;9:353–70.
- Baumgartner F, Jones B. *Agendas and instability in American politics*. Chicago, London: University of Chicago Press, 1993.
- Lipsky M. *Street-level bureaucracy: dilemmas of the individual in public services*. New York: Russel Sage Foundation, 1980.
- Snilstveit B, Oliver S, Vojtkova M. Narrative approaches to systematic review and synthesis of evidence for international development policy and practice. *J Dev Effect* 2012;4:409–29.

**Title:** Implementation of medicines pricing policies in sub-Saharan Africa: protocol for a systematic review

PRISMA-P (preferred reporting items for systematic review and meta-analysis protocols) 2015 checklist: recommended items to address in a systematic review protocol

Section and topic	Item No	Checklist item	Y/N	Page number	Line numbers
<b>Administrative information</b>					
Title:					
Identification	1a	Identify the report as a protocol of a systematic review	Y	1	1-2
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	n/a	n/a	n/a
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	Y	2	67-68
Authors:					
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	Y	1	6-26
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	Y	9	297-299
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	n/a	n/a	n/a
Support:					
Sources	5a	Indicate sources of financial or other support for the review	Y	9	302-304
Sponsor	5b	Provide name for the review funder and/or sponsor	Y	9	302-304
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	Y	9	304-306
<b>Introduction</b>					
Rationale	6	Describe the rationale for the review in the context of what is already known	Y	4	108-126
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	Y	5	129-147
<b>Methods</b>					

<i>Section and topic</i>	<i>Item No</i>	<i>Checklist item</i>	<i>Y/N</i>	<i>Page number</i>	<i>Line numbers</i>
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	Y	5-6	153-186
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	Y	5	154-158
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	Y	6-7	189-212
Study records:					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	Y	7	214-217
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	Y	7	219-224
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	Y	7	226-236
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	Y	7-8	228-236
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	Y	8	251-273
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	Y	7	237-248
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	n/a	n/a	n/a

<i>Section and topic</i>	<i>Item No</i>	<i>Checklist item</i>	<i>Y/N</i>	<i>Page number</i>	<i>Line numbers</i>
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I <sup>2</sup> , Kendall's $\tau$ )	n/a	n/a	n/a
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	n/a	n/a	n/a
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	Y	8	261-269
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	Y	8	258-260
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	Y	8	266-275



Along with Medline we intend to search the following databases:

African Index Medicus (via WHO Global Health Index Medicus) all available years; Embase (Ovid) 1996 present; Global Health (Ovid) 1973 to present; Scopus (Elsevier B.V.) 1823 – Present; Web of Science Core Collection: Citation Indexes (Clarivate Analytics) 1900-present;. We will also search for grey literature and French articles in the following; Cairn International (Cairn Info) all available years; Erudit (University of Montreal ???) all available years; IRIS Institutional Repository for Information Sharing (WHO) all available years and World Bank Group Research and Publications

### Sample Medline strategy

Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily  
<1946 to April 23, 2020>

Search Strategy:

- 
- 1 exp "Africa South of the Sahara"/ (205870)
  - 2 (angola\* or benin\* or botswana\* or "burkina faso" or burundi\*).ti,ab,in,kf. (17906)
  - 3 ("cabo verde\*" or "cape verde\*" or cameroon\* or "central africa\*" or chad or cormoros or congo\* or "ivory coast" or "cote d'ivoire" or djibouti).ti,ab,in,kf. (45277)
  - 4 (guinea\* or eritrea\* or eswatini\* or swaziland\* or ethiopia\* or gabon\* or gambia\* or ghana\* or guinea\*).ti,ab,in,kf. (158364)
  - 5 (kenya\* or lesotho\* or liberia\* or madagascar\* or malawi\* or mali or mauritania\* or mauritius or mozambique\*).ti,ab,in,kf. (55553)
  - 6 (namibia\* or niger or nigeria\* or rwanda\*).ti,ab,in,kf. (67659)
  - 7 ("sao tome" or principe\* or senegal\* or seychelles or "sierra leone\*" or somali\* or "south africa\*" or sudan\*).ti,ab,in,kf. (132358)
  - 8 (tanzania\* or togo\* or uganda\* or zambia\* or zaire\* or zimbabwe\*).ti,ab,in,kf. (50798)
  - 9 (africa\* adj2 ("sub sahara\*" or "south\* sahara\*")).ti,ab,in,kf. (23957)
  - 10 or/1-9 [sub-saharan africa] (519682)
  - 11 Drug Costs/ (15924)
  - 12 ((price? or pricing) adj5 (medicine? or drug? or prescription? or pharmaceutical\*)).tw,kw. (4558)
  - 13 ((cost or costs) adj5 (medicine? or drug? or prescription? or pharmaceutical\*)).tw,kw. (18930)
  - 14 (afford\* adj5 (medicine? or drug? or prescription? or pharmaceutical\*)).tw,kw. (1929)
  - 15 (reimburs\* adj5 (medicine? or drug? or prescription? or pharmaceutical\*)).tw,kw. (2099)
  - 16 (generic\* adj5 (medicine? or drug? or prescription? or pharmaceutical\*)).tw,kw. (4521)
  - 17 exp fees, pharmaceutical/ (2413)

- 18 ((purchas\* or procur\* or expenditure\*) adj5 (medicine? or drug? or prescription? or pharmaceutical\*)).tw,kw. (4913)
- 19 ((subsid\* or tariff\* or incentive\* or containment or transparency) adj5 (medicine? or drug? or prescription? or pharmaceutical\*)).tw,kw. (2141)
- 20 ((fee or fees or rebate\* or payment\* or spend\* or saving\*) adj5 (medicine? or drug? or prescription? or pharmaceutical\*)).tw,kw. (4006)
- 21 ((benchmark\* or cost-plus) adj12 (medicine? or drug? or prescription? or pharmaceutical\*)).tw,kw. (641)
- 22 "low\* price\* generic\*".tw,kw. (76)
- 23 (essential adj2 (drug\* or medicine\*)).tw,kw. (3434)
- 24 Drugs, Essential/ (835)
- 25 (access\* adj3 (medicine? or drug? or prescription? or pharmaceutical\*)).tw,kw. (5991)
- 26 Economics, Pharmaceutical/ (2927)
- 27 (pharma\* adj2 economic\*).tw,kw. (833)
- 28 pharmacoeconomic\*.tw,kw. (3898)
- 29 or/11-28 [drug pricing] (58841)
- 30 exp policy/ (155119)
- 31 Government Regulation/ (21073)
- 32 exp Legislation, Drug/ (32091)
- 33 ((drug\* or medicine\* or pharmaceutical\* or prescription\* or health\*) adj7 (guideline\* or guidance or policy or policies or law or regulat\* or rule\* or legislat\* or control\* or strateg\* or framework\*)).tw,kw. (538082)
- 34 (tax or taxes or exemption\*).tw,kw. (17307)
- 35 ((drug\* or medicine\* or pharmaceutical\* or prescription\* or health\*) adj7 (intervention\* or plan\* or program\*)).tw,kw. (256052)
- 36 or/30-35 [policy concept -all] (917754)
- 37 10 and 29 and 36 [SSA and policy ] (1190)
- 38 Health Plan Implementation/ (5829)
- 39 Program Evaluation/ (62240)
- 40 (barrier\* or facilitator\* or challenge\* or motivator\*).tw,kw. (923252)
- 41 (implement\* or approach\* or process\*).tw,kw. (3962356)
- 42 (factor\* or determinant\* or context\*).tw,kw. (3829825)
- 43 "scal\* up".tw,kw. (19228)

- 44 adopt\*.tw,kw. (243593)
- 45 or/38-44 [implementation] (7698904)
- 46 10 and 29 and 36 and 45 (763)
- 47 limit 46 to yr="2000 -Current" (652)

**AMIPS project: Flowchart for screening of search results**